A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours - Concepedia

Concepedia

Publication | Open Access

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

DOI Full Paper Access

88

Citations

40

References

2014

Year

Irene Braña, Raanan Berger, Talia Golan, Paul Haluska, Jeff Edenfield, J. Fiorica, John Stephenson, Lainie P. Martin, S.N. Westin, P. Hanjani,

British Journal of Cancer

Abstract

Dalotuzumab/MK-2206 and dalotuzumab/MK-0752 combinations were tolerable. Further developments of prospectively validated predictive biomarkers to aid in patient selection for anti-IGF-1R therapies are needed.

References

	Year	Citations

Page 1